Literature DB >> 17517850

Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.

Bruce G Charles1, Ann K Miller, Peter E Nasveld, Mark G Reid, Ivor E Harris, Michael D Edstein.   

Abstract

The population pharmacokinetics of tafenoquine were studied in Australian soldiers taking tafenoquine for malarial prophylaxis. The subjects (476 males and 14 females) received a loading dose of 200 mg tafenoquine base daily for 3 days, followed by a weekly dose of 200 mg tafenoquine for 6 months. Blood samples were collected from each subject after the last loading dose and then at weeks 4, 8, and 16. Plasma tafenoquine concentrations were determined by liquid chromatography-tandem mass spectrometry. Population modeling was performed with NONMEM, using a one-compartment model. Typical values of the first-order absorption rate constant (K(a)), clearance (CL/F), and volume of distribution (V/F) were 0.243 h(-1), 0.056 liters/h/kg, and 23.7 liters/kg, respectively. The intersubject variability (coefficient of variation) in CL/F and V/F was 18% and 22%, respectively. The interoccasion variability in CL/F was 18%, and the mean elimination half-life was 12.7 days. A positive linear association between weight and both CL/F and V/F was found, but this had insufficient impact to warrant dosage adjustments. Model robustness was assessed by a nonparametric bootstrap (200 samples). A degenerate visual predictive check indicated that the raw data mirrored the postdose concentration-time profiles simulated (n = 1,000) from the final model. Individual pharmacokinetic estimates for tafenoquine did not predict the prophylactic outcome with the drug for four subjects who relapsed with Plasmodium vivax malaria, as they had similar pharmacokinetics to those who were free of malaria infection. No obvious pattern existed between the plasma tafenoquine concentration and the pharmacokinetic parameter values for subjects with and without drug-associated moderate or severe adverse events. This validated population pharmacokinetic model satisfactorily describes the disposition and variability of tafenoquine used for long-term malaria prophylaxis in a large cohort of soldiers on military deployment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517850      PMCID: PMC1932489          DOI: 10.1128/AAC.01183-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.

Authors:  G D Shanks; A J Oloo; G M Aleman; C Ohrt; F W Klotz; D Braitman; J Horton; R Brueckner
Journal:  Clin Infect Dis       Date:  2001-11-07       Impact factor: 9.079

2.  Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel.

Authors:  Peter Nasveld; Scott Kitchener; Michael Edstein; Karl Rieckmann
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Nov-Dec       Impact factor: 2.184

Review 3.  Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.

Authors:  Ene I Ette; Paul J Williams; James R Lane
Journal:  Ann Pharmacother       Date:  2004-10-26       Impact factor: 3.154

4.  Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.

Authors:  J A Simpson; R Price; F ter Kuile; P Teja-Isavatharm; F Nosten; T Chongsuphajaisiddhi; S Looareesuwan; L Aarons; N J White
Journal:  Clin Pharmacol Ther       Date:  1999-11       Impact factor: 6.875

5.  Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.

Authors:  M D Edstein; D A Kocisko; T G Brewer; D S Walsh; C Eamsila; B G Charles
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

7.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

8.  A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.

Authors:  Braden R Hale; Seth Owusu-Agyei; David J Fryauff; Kwadwo A Koram; Martin Adjuik; Abraham R Oduro; W Roy Prescott; J Kevin Baird; Francis Nkrumah; Thomas L Ritchie; Eileen D Franke; Fred N Binka; John Horton; Stephen L Hoffman
Journal:  Clin Infect Dis       Date:  2003-02-14       Impact factor: 9.079

Review 9.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

10.  Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.

Authors:  Douglas S Walsh; Chirapa Eamsila; Theerayuth Sasiprapha; Suebpong Sangkharomya; Pradith Khaewsathien; Panpaka Supakalin; Douglas B Tang; Phongsak Jarasrumgsichol; Chainarong Cherdchu; Michael D Edstein; Karl H Rieckmann; Thomas G Brewer
Journal:  J Infect Dis       Date:  2004-09-20       Impact factor: 5.226

View more
  6 in total

1.  Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients.

Authors:  Wei Zhao; Véronique Baudouin; Daolun Zhang; Georges Deschênes; Chantal Le Guellec; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 2.  Tafenoquine and G6PD: a primer for clinicians.

Authors:  Cindy S Chu; David O Freedman
Journal:  J Travel Med       Date:  2019-06-01       Impact factor: 8.490

3.  A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.

Authors:  Geoffrey S Dow; William F McCarthy; Mark Reid; Bryan Smith; Douglas Tang; G Dennis Shanks
Journal:  Malar J       Date:  2014-02-06       Impact factor: 2.979

Review 4.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

5.  Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects.

Authors:  Justin A Green; Apurva K Patel; Bela R Patel; Azra Hussaini; Emma J Harrell; Mirna J McDonald; Nick Carter; Khadeeja Mohamed; Stephan Duparc; Ann K Miller
Journal:  J Clin Pharmacol       Date:  2014-04-09       Impact factor: 3.126

6.  Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.

Authors:  Nilay Thakkar; Justin A Green; Gavin C K W Koh; Stephan Duparc; David Tenero; Navin Goyal
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.